CTOs on the Move

Essilor

www.essilor.com

 
The world`s leading ophthalmic optics company, Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, Bolon™ and Costa®. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of more than €7.1 billion in 2016 and employs 64,000 people worldwide. ...
  • Number of Employees: 5K-10K
  • Annual Revenue: $250-500 Million
  • www.essilor.com
  • 501 Merritt Avenue
    Nashville, TN USA 37203
  • Phone: 615.256.6631

Executives

Name Title Contact Details
Farukh Lakhani
VP - Planning and Analytics Profile

Similar Companies

Surge Medical

Surge Medical Inc. is a Holland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Pyramid Medical Inc

Pyramid Medical Inc is a Los Alamitos, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Putnam Plastics Corporation

Putnam Plastics Corporation is a Dayville, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

GN ReSound North America

GN ReSound North America is a Glenview, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.